Bitter
Disclosed is a method for preparing bitter Ganoderma lucidum spore powder, and relates to the field of drugs or health care products. The method includes: removing visible impurities from Ganoderma lucidum spores, conducting ice bath and heating extraction, filtering through a microfiltration membrane, sterilizing by drying, and conducting sporoderm disruption to obtain the bitter Ganoderma lucidum spore powder. The preparation method effectively improves the content of the bitter substances in the Ganoderma lucidum spore powder by removing shriveled spores through multiple times of impurity removal and filtration in combination with the manner of conducting sporoderm disruption after extraction. Taking the total Ganoderma lucidum triterpenoids in the Ganoderma lucidum spores as a representative of the bitter substances, the content of the total Ganoderma lucidum triterpenoids can reach 5-8%. Meanwhile, the preparation method can also make the content of Ganoderma lucidum polysaccharides reaching 6-10%.
1. A drug or health care product comprising a powder of Ganoderma lucidum spores, wherein the drug or health care product has a dosage form selected from granules, tablets, powders, capsules, oral liquids, injections, sprays, aerosols, power aerosols, lotions, liniments, ointments, emulsions, patches, eye drops, nasal drops, suppositories, pills, microsphere preparations, tinctures, sustained release preparations, controlled release preparations or targeting preparations,
wherein the powder of Ganoderma lucidum spores has been prepared by a method comprising impurity removal, ice bathing and heat extraction, filtration through a microfiltration membrane, sterilization at low pressure, and sporoderm disruption,
wherein the powder of Ganoderma lucidum spores comprises triterpenes in a range of between 5 to 8 percent by mass, and
wherein the powder of Ganoderma lucidum spores comprises polysaccharides in a range of between 6 to 10 percent by mass.
2. The drug or health care product according to claim 1 , further comprising a pharmaceutically acceptable auxiliary material.
3. The drug or health care product according to claim 1 , wherein a content of the bitter Ganoderma lucidum spore powder is no less than 80%.
4. The drug or health care product according to claim 3 , further comprising a pharmaceutically acceptable auxiliary material.